Why the study?
Does nonenzymatic glycosylation of HDL3 reduce its ability to remove cholesterol from cultured cells?
Does nonenzymatic glycosylation of HDL3 reduce its ability to remove cholesterol from cultured cells?
Answers are grounded in this paper and cite their sources.
Nonenzymatic glycosylation of HDL impairs HDL-receptor-mediated cholesterol efflux, suggesting a mechanism for accelerated atherosclerosis in diabetes mellitus.
Previous studies have shown that nonenzymatic glycosylation of high-density lipoprotein (HDL) inhibits high-affinity binding to cultured cells and the candidate HDL-receptor protein. Because binding of HDL to its receptor is required for HDL-receptor-mediated cholesterol efflux from cells, we hypothesized that glycosylated HDL3 would have reduced ability to remove cholesterol from cells. HDL3 was glycosylated in vitro to achieve up to 40-50% reductions in free-lysine residues. Glycosylated HDL3 had a slightly greater ability than control HDL3 to sequester cholesterol directly from the plasma membrane, as predicted by changes in lipid composition. This process is independent of HDL-receptor binding and should not be influenced by reduced binding of HDL3. In contrast, efflux of intracellular cholesterol from cells, which is HDL-receptor dependent, was reduced 25-40%. The ability of glycosylated HDL3 to diminish cholesterol esterification was significantly reduced, indicating reduced net cholesterol efflux. Steady-state efflux of LDL-derived cholesterol was also markedly reduced. These findings suggest that nonenzymatically glycosylated HDL is functionally abnormal and might contribute to the accelerated development of atherosclerosis in patients with diabetes mellitus.
No takes yet. Share an insight, caveat, or question.
Duell et al. (1991) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: